There is a risk of hyperkalaemia if angiotensin II receptor
antagonists are given with amiloride, eplerenone
, particularly if other risk factors (such as advanced age, dose of spironolactone
greater than 25 mg, reduced renal
function and type II diabetes) are also present.
Some manufacturers recommend that the combinations be used cautiously and that serum potassium
should be monitored regularly. However, other manufac- turers advise against concurrent use, which seems overly cautious, if adequate precautions are taken.